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Motivation: Several studies have shown that the reversion of active HSCs to a quiescent state is required for liver fibrosis 
regression. Previous work in our lab have identified GATA4 as key factor for the maintenance of HSCs quiescence. Injection of 
adenovirus overexpressing GATA4 (Ad-GATA4) via the tail vein in CCl4-treated mice have been used as an approach to 
revert the fibrosis. Using this method, adenoviruses are sequestered by all hepatic cells. We will quantify the % of 
Adenoviruses that reach the HSCs and other liver cells to test whether the liver regression is due to the overexpression of 
GATA4 in active HSCs. 
 
A transcriptional repression of HIF2α has been uncover in the group as a molecular mechanism by which GATA4 inactivates 
fibrotic HSCs during liver fibrosis regression. Two conserved GATA sites in the Hif2α gene have been identified. We will test 
whether the repression of Hif2α by GATA4 requires these two GATA sites. Finally, we will develop a vector containing HSCs-
specific enhancer from the Gata4 gene (hG2) fused to a luciferase reporter gene. Using this construct (hG2-luc), we will 
generate a stable cell line to screen FDA-approved drugs that activate Gata4 expression in active (fibrotic) HSCs to induce the 
quiescence. 
  
Methods: Adenovirus overexpressing GFP were injected in mice via the tail vein. Livers from treated mice were analyzed by 
immunofluorescence for GFP and Desmin (HSCs marker) or GFP and HNF1 (hepatocyte marker). Quantification of double 
marked cells will be done using ImageJ software. A region of Hif2α containing wild type or mutated GATA sites was fused to 
the luciferase reporter. 293T cells were transiently transfected with each reporter plasmids and pCI-GATA4 expression vector. 
Luciferase activity was measured using a commercial kit. Finally, we have cloned the HSCs-specific enhancer from the Gata4 
gene into the pGL4-luciferase vector to generate stable LX2 cell line harboring this construct. 
 
Results: Around 50% of HSCs were positive for GFP and Desmin. Mutation of GATA sites in the Hif2α avoid transcriptional 
repression by GATA4. Finally, the pGL4-hG2-TK construction has been successfully generated to develop a stable cell line. 
 
Conclusions: Adenoviruses injection via tail vein in mice efficiently reach HSCs. GATA4 transcriptionally repress Hif2α via 
two identified conserved GATA sites. The hG2-luc construct to generate stable lines will allow us to identified potential drugs to 
induce liver fibrosis regression. 
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